Bottles of the affected lot were marked with a lower strength of 325 mg instead of 500 mg and pose a risk of drug overdose that can lead to liver toxicity or liver failure.
Medline Industries has initiated a voluntary nationwide recall of acetaminophen tablets, 500 mg, uncoated compressed (lot # 45810) due to a labeling error on the packaging. Bottles were marked with a lower strength of 325 mg instead of 500 mg. The error is not easily identifiable by user or prescriber and poses the risk of drug overdose (if the drug is taken at the maximum labeled dose, every four hours, five doses a day, or with other medications containing acetaminophen) that can lead to liver toxicity or liver failure.
Medline says that to date, it has not received any reports of adverse events associated with this product. The company is carrying out investigations to determine the root cases and put in place corrective and preventive action.
Acetaminophen tablets is an over the counter (OTC) oral medication used to temporarily relieve minor aches and pains due to minor pain of arthritis, muscular aches, back aches, headaches, toothaches, the common cold, premenstrual and menstrual cramps, and reduces fever. This item is packaged as 100 tablets per bottle, Medline Item Number: OTC20101, NDC#: 53329-641-30.
The affected lot being recalled was distributed between June 12, 2015 and Sepember18, 2015, with an expiry date of May 2018.
Source: FDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.